Lotus Pharmaceuticals (路坦制药有限公司) filed its 2008 financial report showing the company’s revenues, which totaled $73.8 million, were up 30% while net income rose 14% to $12.8 million or 27 cents per fully diluted share. The company said it expected to see “steady” growth in 2009. Unfortunately, Lotus ended 2008 with just $1.3 million in cash and working capital of $4.4 million with two big-dollar projects in the works. More details...

Stock Symbol: (OTCBB: LTUS)